Status:
COMPLETED
Study to Evaluate Blood and Urine Kidney Injury Markers to Facilitate Early Detection of Renal Adverse Drug Events in Pediatric Cancer Patients Treated With Nephrotoxic Chemotherapy
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
Stiftung für Krebskranke Kinder
Conditions:
Kidney Impairment
Eligibility:
All Genders
Up to 18 years
Brief Summary
This study is to investigate blood and urine kidney injury markers (especially Uromodulin) in pediatric cancer patients treated with nephrotoxic chemotherapy. Uromodulin is a marker to detect and moni...
Eligibility Criteria
Inclusion
- signed informed consent by their-selves (≥ 14 years) or their legal representatives (\< 14 years or in case of lacking capacity of judgement)
- cancer diagnosis, that indicates a nephrotoxic chemotherapy including the drugs High Dose MTX (HD-MTX), ifosfamide, cis- and carboplatin.
Exclusion
- critically-ill patients with inotropic and/or vasopressor drugs
- signs of severe Sepsis
- receiving other nephrotoxic drugs parallel to the chemotherapy cycle
Key Trial Info
Start Date :
October 22 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT04308642
Start Date
October 22 2020
End Date
December 31 2023
Last Update
May 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Children's Hospital Basel (UKBB), University of Basel
Basel, Switzerland, 4056